Monte Rosa Therapeutics (GLUE) Other financing activities (2021 - 2026)

Monte Rosa Therapeutics' Other financing activities history runs 6 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 32200.0% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $10.2 million, a 1134.14% increase from a year earlier, with the FY2025 full-year figure at $5.7 million, up 439.4% from the prior year.
• Other financing activities retreated to $4.5 million in Q1 2026 per GLUE's latest filing, from $5.4 million in the prior quarter.
• Across five years, Other financing activities topped out at $49.8 million in Q2 2024 and bottomed at -$49.3 million in Q3 2024.
• The 5-year median for Other financing activities is $246000.0 (2024), against an average of $810294.1.
• Across the five-year window, Other financing activities plunged 2979.04% in 2024 and surged 32200.0% in 2026, its largest moves.
• Year by year, Other financing activities stood at $439000.0 in 2022, then slumped by 96.81% to $14000.0 in 2023, then jumped by 2607.14% to $379000.0 in 2024, then soared by 1314.51% to $5.4 million in 2025, then slipped by 15.65% to $4.5 million in 2026.
• Per Business Quant, the three latest GLUE Other financing activities figures stand at $4.5 million (Q1 2026), $5.4 million (Q4 2025), and $362000.0 (Q3 2025).